Hutchison China Meditech Limited – American Deposi (NASDAQ:HCM) Shorts Increased By 15.95%

Hutchison China MediTech Limited (NASDAQ:HCM) Corporate Logo

Change of 15.95% for Hutchison China Meditech Limited – American Deposi (NASDAQ:HCM)’s shorted shares was noted. It was published in February by FINRA the 549,500 shorted shares on HCM. That’s 15.95% up from 473,900 shares. Former HCM’s position will need 2 days to restore. It has 338,800 average volume. 1.32% is Hutchison China Meditech Limited – American Deposi float short.

HCM is touching $25.13 during the last trading session, after increased 4.19%.Hutchison China MediTech Limited has volume of 385,413 shares. Since February 14, 2018 HCM has declined 10.14% and is downtrending. HCM underperformed the S&P500 by 10.14%.

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong.The company has $3.32 billion market cap. It operates through Innovation Platform and Commercial Platform divisions.Last it reported negative earnings. The firm discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, makes, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands.

For more Hutchison China MediTech Limited (NASDAQ:HCM) news released briefly go to: Nasdaq.com, Nasdaq.com, Investorplace.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Sage Group Q1 Group Organic Revenue Rises; Reaffirms FY19 Outlook – Quick Facts – Nasdaq” released on January 17, 2019, “Ultimate Software Expands UltiPro Suite With Deloitte Deal – Nasdaq” on October 02, 2018, “5 Potentially Disruptive Software Stock Buyouts for 2019 – Investorplace.com” with a publish date: February 01, 2019, “Stocks To Watch: Those Ticking Clocks – Seeking Alpha” and the last “Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy – Nasdaq” with publication date: December 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.